Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT04289753 Completed - Type 2 Diabetes Clinical Trials

Behavioral Economics Applications to Geriatrics Leveraging EHRs R33 Trial

BEAGLE R33
Start date: September 1, 2020
Phase: N/A
Study type: Interventional

Investigators will evaluate clinical decision support nudges informed by behavioral science and directed at primary care clinicians. These will be used to reduce commonly misused, and potentially harmful, diagnostic and therapeutic actions that occur in the care of older adults (e.g. overtreatment of type 2 diabetes, misuse of PSA screening, misuse of urine testing in women with nonspecific symptoms or no symptoms.

NCT ID: NCT04289454 Completed - Clinical trials for Flavor Perception in Normal, Healthy Adults

Sensory Analysis and Taste Modulation of Ketone Esters

Start date: August 30, 2020
Phase: N/A
Study type: Interventional

Ketone ester (KE) drinks are sold commercially in the USA and elsewhere (the FDA has accepted a GRAS (generally regarded as safe) notification on the KEs we propose to study). KE drinks can have beneficial effects on metabolism. Unfortunately, KE drinks have a strongly unpleasant flavor which can trigger rejection. The current study will generate data to help inform KE drink formulations with improved flavor. First stage, trained subjects will rate the intensity of various sensation qualities (e.g., bitter, sour, metallic, and astringent) from KE drinks to help understand the nature of the unpleasant flavor and the particular sensory systems involved (e.g., taste vs. smell). Then, subjects will taste KE drinks with and without various flavor modifiers. Subjects will be healthy adults (aged 21-45) without known food allergies.

NCT ID: NCT04289194 Completed - Clinical trials for Acute Respiratory Distress Syndrome

Clinical Study to Assess the Safety and Preliminary Efficacy of HCR040 in Acute Respiratory Distress Syndrome

Start date: December 10, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The main objective of the study is to assess the feasibility, safety, and tolerability of the administration of HCR040, a drug whose active substance is HC016, allogeneic adipose-derived adult mesenchymal stem cells expanded and pulsed with H2O2, in patients with acute respiratory distress syndrome.

NCT ID: NCT04289012 Completed - Clinical trials for STEMI - ST Elevation Myocardial Infarction

HELicobacter Pylori Screening in Patients With Acute Myocardial Infarction Pilot Study

HELPpilot
Start date: November 7, 2019
Phase: N/A
Study type: Interventional

The aim of this study is to determine the prevalence of Helicobacter pylori (Hp) infection in patients with myocardial infarction (MI). This is performed to establish the feasibility of a large trial examining whether systematic screening for and subsequent eradication therapy significantly reduces the risk of hospitalization for upper gastrointestinal (GI) bleeding in patients after MI.

NCT ID: NCT04288752 Completed - Clinical trials for Sexual Dysfunction, Physiological

Efficacy of VR101 as a Personal Lubricant

Start date: February 26, 2020
Phase: N/A
Study type: Interventional

This Clinical Investigation (CI03) is designed to validate the efficacy of the VR101 lubricating Intravaginal Ring (IVR) as a personal lubricant device. In the proposed clinical investigation, participants will be randomized into two groups for the study, VR101 Active Ring and Inactive Ring. Participants will use VR101 active rings or inactive rings for 28 days in a randomized, double-blind, parallel group design. The study also includes an optional two-week open-label extension with active rings, and a one-week follow-up.

NCT ID: NCT04288622 Completed - Clinical trials for Women at Risk of Common Mental Disorders

ESM-derived Personalised Feedback for Women at Risk of Common Mental Disorder

Start date: March 1, 2020
Phase: N/A
Study type: Interventional

This study aims to examine the effectiveness of Experience Sampling Method (ESM) derived personalised feedback for women at risk of common mental disorder in Hong Kong, in reducing individuals depressive and anxiety symptoms.

NCT ID: NCT04288544 Completed - Micronutrients Clinical Trials

"Health Promoting Effects of the Microalgae Phaeodactylum Tricornutum"

UniHoh-Algen
Start date: February 25, 2020
Phase: N/A
Study type: Interventional

The aim of the research project is to investigate the uptake of omega-3 fatty acids into the blood plasma through the consumption of the microalgae Phaeodactylum tricornutum (PT) in a human study. In an open, crossover study, the volunteers will receive a drink enriched with the microalgae P. tricornutum or an omega-3 fatty acid preparation or (optionally) pollock for 14 days each. Since the microalgae P. tricornutum is rich in omega-3 fatty acids, the target parameter chosen is the uptake of omega-3 fatty acids in the blood plasma

NCT ID: NCT04288440 Completed - Clinical trials for Rhegmatogenous Retinal Detachment of Both Eyes (Diagnosis)

Characters of Epiretinal Membranes in Patients With Previous Vitrectomy for Retinal Detachment

RD
Start date: January 1, 2019
Phase: N/A
Study type: Interventional

31 patients were included in the study,15 cases with ERM in silicone filled eyes and 16 eyes with idiopathic ERM

NCT ID: NCT04288284 Completed - Colorectal Cancer Clinical Trials

Emergency Curative Resection of Colorectal Cancer

Start date: January 2015
Phase:
Study type: Observational

The feasibility and efficacy of emergency curative resection of complicated colorectal cancer is still controversial. This prospective study aim is to assess surgical and oncologic outcomes after emergency compared to elective curative resection of colorectal cancer

NCT ID: NCT04288232 Completed - Clinical trials for Center-involved Diabetic Macular Edema

Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan

Start date: August 31, 2015
Phase: Phase 3
Study type: Interventional

Phase IIIb, multicenter, open-label, prospective, interventional study to assess the potential benefit of Aflibercept treatment administered IVT at a dosage of 2 mg with five monthly loading doses and then treat and extend over 48 weeks, with the primary endpoint as BCVA assessed at Week 52.